ASCO GI 2022 Conference Coverage

 

Videos
12:45

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Biliary Cancer Updates

FEATURING Kristen Spencer
  • 52 views
  • May 20, 2022
  • 1
09:37

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates in HCC

FEATURING Saeed Sadeghi
  • 90 views
  • March 11, 2022
05:42

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Pembro +/- Chemo vs. Chemo Alone for PD-L1+ Advanced GC/GEJC: Update From the Phase 3 KEYNOTE-062 Trial

FEATURING Zev A. Wainberg
  • 507 views
  • February 14, 2022
  • 1
14:06

ASCO GI 2022 Conference Coverage

ASCO GI 2022 on the Emerging Roles of ctDNA as a Tool in Metastatic GI Cancers

FEATURING Arvind Dasari
  • 238 views
  • February 3, 2022
  • 1
08:15

ASCO GI 2022 Conference Coverage

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis in CheckMate 649: Nivo + Chemo vs. Chemo as 1L Treatment for Advanced GC/GEJC/EAC

FEATURING Ryan Sugarman
  • 425 views
  • February 3, 2022
11:37

ASCO GI 2022 Conference Coverage

ASCO GI 2022 CRC Cases: Is It Time to De-Intensify Oxaliplatin to Improve Patient Outcomes?

FEATURING Gabriel A. Brooks
  • 256 views
  • February 1, 2022
  • 2
06:54

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Results From the PREVAIL ctDNA Study: Liquid Biopsy for Diagnosis of Suspected Pancreatic & Biliary Tract Cancers

FEATURING Justin Mencel
  • 134 views
  • February 1, 2022
13:14

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights on a Multicenter Phase II Study of Neoadjuvant Nivo+/-Relatlimab + CRT in Stage II/III EC/GEJC

FEATURING Ronan Kelly
  • 128 views
  • February 1, 2022
13:50

ASCO Gastrointestinal Cancers Symposium

[PRIVATE - new ASCO version uploaded] ASCO GI 2022 Updates on the Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E mCRC

FEATURING Van Morris
  • 225 views
  • February 1, 2022
  • 2
20:21

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Review of the Emerging Roles of ctDNA as a Tool for Early Diagnosis of GI Cancers

FEATURING Naureen Starling
  • 363 views
  • February 1, 2022
  • 2
05:49

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Study of T-DXd Monotherapy and Combinations in Advanced /Metastatic HER2+ GC/GEJA: DESTINY-Gastric03

FEATURING Yelena Y. Janjigian
  • 222 views
  • February 1, 2022
08:07

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Phase I/II Study of Regorafenib and Pembrolizumab in Refractory MSS CRC

FEATURING Afsaneh Barzi
  • 227 views
  • February 1, 2022
12:23

ASCO GI 2022 Conference Coverage

ASCO GI 2022 on Chemo and CRT Neoadjuvant Regimens for Locally Advanced Esophageal Cancer: Phase 3 JCOG1109 NExT Study

FEATURING Ken Kato
  • 197 views
  • January 26, 2022
22:39

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on Integrating New Targeted Therapy Into Locoregional Treatment of Localized ICC

FEATURING Flavio Rocha
  • 375 views
  • January 26, 2022
  • 3
05:54

ASCO GI 2022 Conference Coverage

ASCO GI 2022 on mFOLFOX6/Bev +/- Nivo for 1L Treatment of mCRC: Phase 2 Results From CheckMate 9X8

FEATURING Heinz-Josef Lenz
  • 480 views
  • January 26, 2022
  • 4
14:00

ASCO GI 2022 Conference Coverage

ASCO GI 2022 on Triplet vs. Doublet Systemic Therapy for Advanced Rectal Cancer: Why Would We Escalate

FEATURING Hanna K. Sanoff
  • 315 views
  • January 26, 2022
  • 1
10:58

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on FOLFOX + nab-Paclitaxel (FOLFOX-A) in the Treatment of Advanced/Metastatic Unresectable GC/GEJC - Big Ten Cancer Research Consortium Trial

FEATURING Al Benson
  • 431 views
  • January 26, 2022
05:04

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IO for Early Stage HCC

FEATURING Augusto Villanueva
  • 165 views
  • January 26, 2022
05:07

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Long-Term Follow-Up of the GERCOR NIPICOL Study: One-Year Duration of Nivo+Ipi in MSI-H/dMMR mCRC

FEATURING Romain Cohen
  • 432 views
  • January 26, 2022
  • 4
08:49

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Update on NIVO+ Chemo vs Chemo as 1L Treatment for Advanced GC/GEJC/EAC: Expanded Efficacy, Safety, and Subgroup Analyses From 24-month Follow-up of CheckMate 649

FEATURING Kohei Shitara
  • 421 views
  • January 26, 2022
07:30

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IMbrave150 Trial: Exploratory Efficacy & Safety in Unresectable HCC Treated With Atezo Beyond Radiological Progression Until the Loss of Clinical Benefit

FEATURING Han Chong Toh
  • 84 views
  • January 26, 2022
04:05

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights: Host-Related Biomarkers Including Gut Microbiome to Predict Toxicities of Nivolumab in Advanced Gastric Cancer - DELIVER Trial (JACCRO GC-08)

FEATURING Yu Sunakawa
  • 184 views
  • January 26, 2022
09:44

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights: Clinical Utility of MSI-H Identified on Liquid Biopsy in Advanced Gastrointestinal Cancers

FEATURING Pashtoon Kasi
  • 359 views
  • January 26, 2022
  • 2